多预测器风险模型用于预测阿尔茨海默病的个体风险
Xiao-He Hou1, John Suckling2, Xue-Ning Shen3
1Department of Neurology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
Journal of translational medicine
|October 31, 2023
概括
开发个性化的阿尔茨海默病 (AD) 风险模型,用于早期预防. 这些模型准确地预测了轻度认知障碍和正常认知的个体的AD发病,有助于及时干预策略.
科学领域:
- 神经科学是一个神经科学.
- 生物统计学 生物统计学
- 医疗信息学 医疗信息学
背景情况:
- 早期预防阿尔茨海默病 (AD) 对于延迟发病和进展至关重要.
- 个人级别的AD预测对于有效的预防策略至关重要.
- 这项研究的重点是开发个体患者层面的AD预测风险模型.
研究的目的:
- 开发和验证风险模型,以预测阿尔茨海默病 (AD) 在个人层面的发病.
- 从各种特征中确定一组最佳的预测因子,用于AD风险评估.
- 帮助早期预防和管理AD.
主要方法:
- 利用来自阿尔茨海默氏病神经成像计划的487名认知正常 (CN) 和796名轻度认知障碍 (MCI) 个体的数据.
- 收集了临床,认知,MRI和CSF标记,随访期为5.6年 (CN) 和4.6年 (MCI).
- 应用最小绝对收缩和选择运算符 (LASSO) 考克斯回归用于预测器选择和模型构建.
主要成果:
- 在5年内,CN模型预测了prodromalAD的AUC值为0.81;139名CN参与者进展.
- 在5年内,MCI模型预测了AD痴呆症,AUC为0.92;321名MCI患者进展.
- 一个阿尔茨海默氏症连续模型实现了高精度 (AUC=0.91) 预测在3年内进展.
结论:
- 开发了个性化,年复一年的AD发病风险模型.
- 模型显示,对于正常认知和MCI的个体,预测准确度很高.
- 这些风险模型为增强AD预防策略提供了有价值的工具.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
相关概念视频
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
